In 251 adults and adolescents with HIV on ART with undetectable viral load, one dose of rVSVΔG-ZEBOV-GP Ebola vaccine raised GP-ELISA antibodies over 40-fold vs placebo (GMTR 42·90); a second dose gave a GMTR of 208·66. Adverse events were mild to moderate and transient.
RCTn = 251
Tremblay et al. Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial